Cadaveric pituitary-derived growth hormone delivery influences iatrogenic Alzheimer’s Disease

Recipients of cadaver-derived pituitary growth hormone (c-hGH) developed biomarker changes in the realm of Alzheimer’s disease (AD).

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

A fixed-duration, three-drug regimen for chronic lymphocytic leukemia (CLL) achieved deep and durable remissions lasting for up to 7 years, according to updated results from

June 18, 2024

Measurable Cognitive Deficits Linked to Long COVID

Measurable cognitive deficits persisted after SARS-CoV-2 infection, a large observational study in England showed. People with COVID symptoms that lasted 12 weeks or longer (i.e.,

March 1, 2024

Psychedelic Bulletin #147: Newsom Vetoes Psychedelic Decrim. in CA; At-Home Ketamine Gets a Lifeline and a Warning; Drug Development Updates from GH, atai, Cybin; and more – Psychedelic Alpha

On Saturday October 7th California’s Governor, Gavin Newsom, returned Senate Bill 58 to the Senate without his signature, effectively vetoing it. As a reminder, SB

October 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.